Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Lal
Suman
S
Laboratory of Clinical Pharmacology, Division of Medical Sciences, Humphrey Oei Institute of Cancer Research National Cancer Centre, 11 Hospital Drive, Singapore 169610.
Mahajan
Anupama
A
Chen
Wei Ning
WN
Chowbay
Balram
B
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics; D001711:Biotransformation / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy / Q000208:ethnology / Q000235:genetics / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D004317:Doxorubicin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D055432:Metabolomics; D010597:Pharmacogenetics; D057285:Precision Medicine; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D002352:Carrier Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D004317:Doxorubicin